Chidozie Ugwumba Sells 12,432 Shares of Clene (NASDAQ:CLNN) Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 12,432 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $4.80, for a total transaction of $59,673.60. Following the sale, the insider owned 629,943 shares in the company, valued at $3,023,726.40. The trade was a 1.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The shares were sold at an average price of $5.05, for a total value of $61,200.95.
• On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The shares were sold at an average price of $5.13, for a total value of $40,644.99.
• On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The shares were sold at an average price of $5.10, for a total transaction of $64,071.30.
• On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The shares were sold at an average price of $5.12, for a total transaction of $100,459.52.
• On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The stock was sold at an average price of $4.89, for a total value of $127,653.45.
• On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The stock was sold at an average price of $5.50, for a total transaction of $179,877.50.
• On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $56,900.25.
• On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The shares were sold at an average price of $6.09, for a total value of $19,457.55.
• On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The shares were sold at an average price of $6.29, for a total value of $24,770.02.
• On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The shares were sold at an average price of $6.04, for a total transaction of $18,790.44.

Clene Stock Performance

NASDAQ:CLNN traded up $0.46 during trading hours on Wednesday, reaching $5.19. The company’s stock had a trading volume of 131,571 shares, compared to its average volume of 99,286. The firm has a market capitalization of $56.31 million, a price-to-earnings ratio of -1.53 and a beta of 0.87. The firm has a 50-day simple moving average of $6.94 and a 200-day simple moving average of $6.50. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50.

Clene (NASDAQ:CLNN) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.06 million. Equities analysts anticipate that Clene Inc. will post -5.19 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CLNN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Clene in a research report on Friday, January 9th. Benchmark restated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. UBS Group reaffirmed a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Finally, D. Boral Capital reiterated a “buy” rating and issued a $23.00 price objective on shares of Clene in a report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

Institutional Investors Weigh In On Clene

Large investors have recently bought and sold shares of the business. Scoggin Management LP grew its stake in shares of Clene by 75.1% in the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after acquiring an additional 107,250 shares during the period. Lunt Capital Management Inc. boosted its holdings in Clene by 2.5% in the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after purchasing an additional 1,250 shares during the last quarter. Jane Street Group LLC bought a new stake in Clene in the 2nd quarter worth approximately $47,000. Finally, Jones Financial Companies Lllp purchased a new stake in Clene during the 3rd quarter valued at $29,000. 23.28% of the stock is currently owned by institutional investors.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).